Araclon Biotech

Executive Summary

Araclon Biotech, a subsidiary of Grifols, is a Spanish biotechnology company dedicated to the early diagnosis and preventive treatment of Alzheimer's disease. The company has developed proprietary plasma-based diagnostic assays that detect amyloid-beta peptides, enabling identification of pathological changes before clinical symptoms appear. This approach positions Araclon as a pioneer in non-invasive early detection, potentially revolutionizing Alzheimer's management. The diagnostic platform leverages Grifols' expertise in plasma fractionation and large-scale manufacturing, providing a commercial advantage. Araclon's lead diagnostic product is advancing toward regulatory submission, with strong potential to become a standard screening tool for Alzheimer's risk assessment. Beyond diagnostics, Araclon is advancing a therapeutic vaccine targeting amyloid-beta, aiming to slow or prevent disease progression. The vaccine has shown promise in preclinical and early clinical studies, with next-phase trials expected to read out in 2026. Additionally, the company has initiated a diversification program into Parkinson's disease, exploring similar diagnostic and therapeutic approaches. Backed by Grifols' resources and a robust pipeline, Araclon is well-positioned to address the growing neurodegenerative disease market. Success in its current programs could establish the company as a leader in precision neurology, with significant impact on patient outcomes and healthcare costs.

Upcoming Catalysts (preview)

• Q2 2026Diagnostic assay regulatory submission (IVDR or FDA)70% success
• Q4 2026Therapeutic vaccine Phase 2 interim data readout50% success
• Q3 2026Parkinson's disease program preclinical proof-of-concept data60% success